Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463426 | 0.98 | CNR2 (0.45) | CNR2SIGMAR1CNR1FSCN1ADRA1D | |
| SCHEMBL5454163 | 0.92 | CNR2 (0.52) | CNR2SIGMAR1CNR1APEX1PDE10A | |
| SCHEMBL5462928 | 0.91 | CNR2 (0.44) | CNR2CNR1FSCN1APEX1 | |
| SCHEMBL14463739 | 0.91 | CNR2 (0.41) | CNR2SIGMAR1CNR1ADRA1DADRA1A | |
| SCHEMBL5446369 | 0.90 | PTPN7 (0.44) | CNR2CNR1FSCN1APEX1 | |
| SCHEMBL5448680 | 0.90 | CNR2 (0.46) | CNR2ADRA1DADRA1AADRA1BPDE10A | |
| SCHEMBL5454762 | 0.89 | CNR2 (0.50) | CNR2SIGMAR1CNR1APEX1PDE10A | |
| SCHEMBL5451293 | 0.89 | CNR2 (0.42) | CNR2CNR1FSCN1APEX1 | |
| SCHEMBL5450158 | 0.89 | CNR2 (0.41) | CNR2CNR1FSCN1APEX1PDE10A | |
| SCHEMBL14411415 | 0.89 | PTPN7 (0.42) | CNR2CNR1FSCN1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885SIGMAR1 175/4885CNR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.